Pyankov Oleg V, Bodnev Sergey A, Pyankova Olga G, Solodkyi Vladislav V, Pyankov Stepan A, Setoh Yin Xiang, Volchkova Valentina A, Suhrbier Andreas, Volchkov Viktor V, Agafonov Alexander A, Khromykh Alexander A
State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation.
State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia.
J Infect Dis. 2015 Oct 1;212 Suppl 2(Suppl 2):S368-71. doi: 10.1093/infdis/jiv019. Epub 2015 Mar 2.
The current unprecedented outbreak of Ebola virus (EBOV) disease in West Africa has demonstrated the urgent need for a vaccine. Here, we describe the evaluation of an EBOV vaccine candidate based on Kunjin replicon virus-like particles (KUN VLPs) encoding EBOV glycoprotein with a D637L mutation (GP/D637L) in nonhuman primates. Four African green monkeys (Cercopithecus aethiops) were injected subcutaneously with a dose of 10(9) KUN VLPs per animal twice with an interval of 4 weeks, and animals were challenged 3 weeks later intramuscularly with 600 plaque-forming units of Zaire EBOV. Three animals were completely protected against EBOV challenge, while one vaccinated animal and the control animal died from infection. We suggest that KUN VLPs encoding GP/D637L represent a viable EBOV vaccine candidate.
目前西非爆发的前所未有的埃博拉病毒（EBOV）病表明迫切需要一种疫苗。在此，我们描述了在非人类灵长类动物中对一种基于编码带有D637L突变的埃博拉病毒糖蛋白（GP/D637L）的库京复制子病毒样颗粒（KUN VLPs）的埃博拉病毒疫苗候选物的评估。4只非洲绿猴（非洲长尾猴）每只皮下注射一剂10⁹个KUN VLPs，间隔4周注射两次，3周后对动物进行肌肉注射600个扎伊尔埃博拉病毒空斑形成单位的攻击。3只动物完全抵御了埃博拉病毒攻击，而1只接种疫苗的动物和对照动物死于感染。我们认为编码GP/D637L的KUN VLPs是一种可行的埃博拉病毒疫苗候选物。
